新華醫療(600587.SH)預計2019年淨利增加8.75億元-8.86億元
格隆匯1月21日丨新華醫療(600587.SH)發佈2019年年度業績預告,預計2019年度實現歸屬於上市公司股東的淨利潤與上年同期(法定披露數據)2278.41萬元相比,增加8.75億元到8.86億元。歸屬於上市公司股東的扣除非經常性損益的淨利潤與上年同期(法定披露數據)-6536.36萬元相比,將增加6574.37萬元到7713.58萬元。
公司本次業績預告中扣除非經常性損益變動的主要原因包括:(1)公司報告期內計提商譽減值準備974.39萬元較去年同期1.22億元減少1.12億元;(2)報告期內,剔除上海方承醫療器械有限公司(以下簡稱“上海方承”)和威士達醫療有限公司(以下簡稱“威士達”)不再納入合併報表的影響後,公司醫療器械、醫療商貿板塊業績增長穩中有升;(3)製藥裝備板塊受市場競爭激烈、藥物一致性評價、成都英德生物醫藥裝備技術有限公司和上海遠躍製藥機械有限公司收入確認政策等因素影響,業務尚處於恢復期;(4)2019年上海方承不再納入合併報表,導致公司淨利潤減少。
公司本次業績預增主要是由於非經常性損益事項所致,非經常性損益事項主要包括:(1)報告期內公司出售了蘇州長光華醫生物醫學工程有限公司8.2041%的股權,增加投資收益9441.75萬元;(2)報告期內公司出售了威士達60%的股權,增加投資收益(包括特別股息)7.79億元。兩項股權出售合計增加投資收益8.74億元。
公司通過增資方式為全資子公司山東省文登整骨煙台醫院有限公司(以下簡稱“煙台醫院”)引進戰略投資者,增資完成後,煙台醫院由全資子公司變更為公司的聯營企業,不再納入合併報表範圍,在長期股權投資科目歸集,按照權益法進行核算。煙台醫院增資擴股事項預計增加投資收益8996.21萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.